Sionna Therapeutics Income Statement (2024-2026) | SION

Income Statement Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter) 10.22M8.23M24.58M14.25M13.67M15.38M16.04M15.17M18.96M
Selling, General & Administrative (Quarter) 2.93M3.06M3.40M3.88M5.99M6.52M7.76M8.44M10.64M
Operating Expenses (Quarter) 13.15M11.29M27.98M18.13M19.66M21.91M23.80M23.61M29.60M
Operating Income (Quarter) -13.15M-11.29M-27.98M-18.13M-19.66M-21.91M-23.80M-23.61M-29.60M
EBIT (Quarter) -13.15M-11.29M-27.98M-18.13M-19.66M-21.91M-23.80M-23.61M-29.60M
Non-operating items
Interest & Investment Income (Quarter) 1.13M2.57M2.35M2.12M3.00M3.67M3.46M3.17M2.82M
Other Non Operating Income (Quarter) 0.17M0.17M0.19M0.17M0.18M0.17M0.07M
Non Operating Income (Quarter) 1.30M2.74M2.54M2.29M3.18M3.84M3.53M3.17M2.82M
Net income details
EBT (Quarter) -12.02M-8.73M-25.63M-16.01M-16.66M-18.24M-20.35M-20.44M-26.78M
Profit After Tax (Quarter) -11.85M-8.55M-25.44M-15.85M-16.48M-18.07M-20.28M-20.44M-26.78M
Income from Continuing Operations (Quarter) -12.02M-8.73M-25.63M-16.01M-16.66M-18.24M-20.35M-20.44M-26.78M
Consolidated Net Income (Quarter) -12.02M-8.73M-25.63M-16.01M-16.66M-18.24M-20.35M-20.44M-26.78M
Income towards Parent Company (Quarter) -12.02M-8.73M-25.63M-16.01M-16.66M-18.24M-20.35M-20.44M-26.78M
Net Income towards Common Stockholders (Quarter) -12.02M-8.73M-25.63M-16.01M-16.66M-18.24M-20.35M-20.44M-26.78M
Additional items
EPS (Basic) (Quarter) -0.00M-0.00M-5.67-3.18-0.62-410.00-0.46-0.45-0.60
EPS (Weighted Average and Diluted) (Quarter) -0.00M-0.00M-5.67-3.18-0.62-410.00-0.46-0.45-0.60
Shares Outstanding (Weighted Average) (Quarter) 3.08M3.12M3.58M3.86M26.60M35.40M38.39M39.96M44.92M
Shares Outstanding (Diluted Average) (Quarter) 3.08M3.16M3.58M3.86M26.60M35.40M44.26M39.96M44.92M
EBITDA (Quarter) -11.86M-8.70M-24.51M-16.25M-16.55M-18.19M-20.04M-20.32M-27.40M
Shares Outstanding (Quarter) 3.10M3.18M4.66M4.72M44.09M44.13M44.46M44.72M45.08M